Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

87
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
87
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

271
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
271
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

278
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
278
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

268
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
268
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

3.0K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

304
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
304

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to 'Skin as the target for allergy prevention and treatment' [Annals of Allergy, Asthma & Immunology, Volume 133, Issue 2 (2024) 133-143].

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

IKAROS Family Transcription Factors in Lymphocyte Differentiation and Function.

Advances in experimental medicine and biology·2024
Same author

Kidins220 and Aiolos promote thymic iNKT cell development by reducing TCR signals.

Science advances·2024
Same author

Skin as the target for allergy prevention and treatment.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2024
Same author

Topical steroid withdrawal and atopic dermatitis.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2023
Same author

Evolution of the Ikaros family transcription factors: From a deuterostome ancestor to humans.

Biochemical and biophysical research communications·2023

Related Experiment Video

Updated: Nov 8, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.4K

Biologics in atopic dermatitis.

Susan Chan1,2

  • 1Paediatric Allergy Group, Department of Women and Children's Health, School of Life Course Sciences, King's College London, St. Thomas' Hospital.

Current Opinion in Allergy and Clinical Immunology
|April 19, 2021
PubMed
Summary

New biological therapies offer hope for severe atopic dermatitis unresponsive to topical treatments. This review covers recent advancements and ongoing studies in biologic treatments for atopic dermatitis.

More Related Videos

Author Spotlight: Effective Reuse of Polycarbonate Tubes for Extracellular Vesicle Isolation
02:36

Author Spotlight: Effective Reuse of Polycarbonate Tubes for Extracellular Vesicle Isolation

Published on: March 8, 2024

1.3K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K

Related Experiment Videos

Last Updated: Nov 8, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.4K
Author Spotlight: Effective Reuse of Polycarbonate Tubes for Extracellular Vesicle Isolation
02:36

Author Spotlight: Effective Reuse of Polycarbonate Tubes for Extracellular Vesicle Isolation

Published on: March 8, 2024

1.3K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Limited systemic therapy options existed for refractory atopic dermatitis.
  • Recent years have seen significant advancements in biologic treatments.

Purpose of the Study:

  • To review recent literature and ongoing studies on biological therapies for atopic dermatitis.
  • To highlight progress in managing atopic dermatitis unresponsive to topical treatments.

Main Methods:

  • Literature review of recent studies on biologicals in atopic dermatitis.
  • Analysis of ongoing clinical trials for new biologic therapies.

Main Results:

  • Dupilumab is effective and approved for moderate-to-severe atopic dermatitis.
  • Tralokinumab is under regulatory review; other biologics are in development.
  • Evidence supports biologic use in children and for multisystemic involvement.

Conclusions:

  • Breakthroughs in biologic therapies address a critical unmet need in atopic dermatitis management.
  • These advancements offer new hope for patients with severe disease refractory to topical therapies.